Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Votrient - NPS MedicineWise
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
Survival distributions for progression-free (PFS) and overall survival... | Download Scientific Diagram
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma - ScienceDirect
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma | PNAS
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation | BMC Cancer
Votrient, pazopanib
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study - Clinical Genitourinary Cancer
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation | BMC Cancer
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer | Future Oncology
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - Gynecologic Oncology
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
820-Renal cell metastatic pAZOPanib | eviQ
Clinical Trials | VOTRIENT® (pazopanib) tablets
Progression free survival for patient with metastatic bone sarcoma... | Download Scientific Diagram
